SIRAKOSS
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Ulls Väg 29c, Uppsala, Uppsala County, 7...Website
www.sirakoss.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About SIRAKOSS
OssDsign is a developer and global provider of next generation orthobiologics products, focusing on cutting-edge material science to enhance the body's healing capabilities. Their flagship product, OssDsign Catalyst, is a nanosynthetic bone graft designed for rapid and reliable bone formation, particularly in interbody fusion applications. The company aims to give patients back the life they deserve by providing innovative solutions for spine surgery. Their intended clients include orthopedic surgeons and healthcare professionals seeking advanced bone graft options.Explore more
SIRAKOSS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SIRAKOSS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SIRAKOSS had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at SIRAKOSS
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on SIRAKOSS recently announced quarterly report
Product Launch: Get notified when SIRAKOSS launches new products
SIRAKOSS, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if SIRAKOSS is spiking on competitors!
Check if SIRAKOSS has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once SIRAKOSS has new funding data
Recommended Actions
Reach out to Masked Content who joined SIRAKOSS as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
SIRAKOSS is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SIRAKOSS is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SIRAKOSS.
SIRAKOSS financials insights
Gather financial insights about SIRAKOSS, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$4.8M
SIRAKOSS Tech Stack
A closer look at the technologies used by SIRAKOSS
See more technologies
SIRAKOSS News & Media
OssDsign has carried out a directed share issue raising proceeds of approximately SEK 65 million to finance the Sirakoss acquisition
The Board of Directors of OssDsign AB (publ) (”OssDsign” or the ”Company”) has, as communicated in the Company’s press release earlier today, resolved to carry out a directed share issue of 4,433,292 shares (corresponding to 25 percent of the total number of outstanding shares and votes in the Company) at a subscription price of SEK 14.70 per share (the “Directed Issue”). Due to the Directed Issue being heavily over-subscribed by a large number of SwedishOssDsign acquires Sirakoss, enters USD 4 billion bone graft market
OssDsign AB (publ) (“OssDsign”), a leading bone-regeneration company with headquarters in Uppsala, Sweden, today announces the signing of an agreement to acquire the privately held, Scottish bone graft specialist company Sirakoss Ltd (“Sirakoss”). The acquisition broadens OssDsign’s product portfolio with the 510(k) cleared Osteo[3] ZP Putty, a next-generation synthetic bone graft substitute for use in orthopaedic surgery. OssDsign acquires all outstanding Sirakoss shares in an all-cash transactSIRAKOSS Receives U.S. FDA 510(k) Clearance for Osteo3 ZP Putty to Catalyse Rapid and Complete Bone Regeneration
ABERDEEN, Scotland--(BUSINESS WIRE)--SIRAKOSS has received 510(k) clearance from the US Food and Drug Administration for Osteo3 ZP Putty, its new nanosynthetic bone graft substitute.SIRAKOSS Receives CE Mark for Osteo3 Synthetic Bone Graft Substitute
ABERDEEN, Scotland--(BUSINESS WIRE)--SIRAKOSS has received CE Mark in EU for Osteo3, a novel nanosynthetic bone graft substitute designed to improve patient healing.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SIRAKOSS
Sign Up For FreeTo access detailed company insights
OssDsign is a developer and global provider of next generation orthobiologics products, focusing on cutting-edge material science to enhance the body's healing capabilities. Their flagship product, OssDsign Catalyst, is a nanosynthetic bone graft designed for rapid and reliable bone formation, particularly in interbody fusion applications. The comp... Read More
